Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243	NDA	Janssen Pharmaceuticals Inc.	50458-028-02	2 BLISTER PACK in 1 KIT (50458-028-02) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)	2019-03-05
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243	NDA	Janssen Pharmaceuticals Inc.	50458-028-03	3 BLISTER PACK in 1 KIT (50458-028-03) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)	2019-03-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 25, 2026

Suppliers for SPRAVATO (esketamine) nasal spray: contract manufacturers, key API/part supply, and regulatory supply-chain exposure

Executive summary: SPRAVATO (esketamine) nasal spray is supplied through a tight, regulated supply chain covering (1) esketamine API sourcing and formulation development, (2) nasal spray device/primary packaging components, and (3) US release and distribution under FDA GMP. Publicly actionable supplier identification is limited because the FDA Orange Book does not list suppliers, and the prescribing label typically does not name upstream contract manufacturing or API vendors.

If you need a defensible supplier map for licensing, litigation, or generic entry risk, the usable public path is FDA labeling supply-chain references plus Orange Book NDA/NDC linkages plus CGMP inspection records and company disclosures. Without those specific records for this query scope, supplier identification cannot be completed accurately.

Which companies supply the esketamine API and nasal spray for SPRAVATO in the US?

Direct answer: The public materials for SPRAVATO that are routinely available (FDA label and Orange Book) do not provide a complete, supplier-level breakdown of esketamine API and finished-dose contract manufacturing for the US supply chain.

What typically counts as “supplier” in SPRAVATO procurement

In practice, procurement teams treat “supplier” as one or more of the following:

API manufacturer for esketamine hydrochloride (or the relevant salt form used in the product)
Drug-product contract manufacturer assembling and filling the nasal spray
Device supplier for the nasal delivery system components
Packaging supplier (bottles, closures, overwrap, cartons) and serialization/labeling partners
Cold-chain logistics providers if temperature controls apply across the distribution lane
Labeler/marketing authorization entity responsible for US release

Why Orange Book does not answer this

Orange Book listings attach to patents and submissions (NDA, dosage form, marketing exclusivity), not to upstream supplier names. It lists patents tied to the NDA, not who manufactures the API, fills, or supplies the pump assembly. As a result, “which company supplies SPRAVATO” cannot be answered from Orange Book alone.

What is the Orange Book status of SPRAVATO, and does it identify manufacturers or suppliers?

Direct answer: Orange Book status is patent and exclusivity focused and does not identify upstream suppliers.

Orange Book and exclusivity pointers used in supply-chain due diligence

Supply-chain diligence usually couples Orange Book with:

NDC-to-manufacturer mapping (labeler on the labeler code)
FDA product listing records (structured product information)
Inspection lists for manufacturing sites
Corporate disclosures in annual reports and investor presentations

Key limitation for supplier identification

Even when you identify the US labeler and manufacturing site, upstream API suppliers and device vendors often remain undisclosed unless they appear in:

FDA inspection publications for specific sites
Drug establishment registration details
Public GMP warning letters that cite the manufacturing entity
Contract manufacturing press releases

Who are the SPRAVATO contract manufacturers and finished-dose fill suppliers?

Direct answer: A complete, citation-grade list of SPRAVATO contract manufacturers and fill suppliers is not available from the core public sources commonly used for a supplier query. Supplier identification requires site-level manufacturing disclosures or inspection-linked evidence.

Where contract manufacturers are usually discoverable (and why it matters)

For regulated nasal spray products like SPRAVATO, CMO roles commonly include:

Formulation blending of the nasal spray composition
Filling and finishing into the nasal device system
Container closure integrity testing
In-process controls for content uniformity and spray characteristics
Serialization and release testing aligned with FDA batch disposition

Without site registration or inspection-linked evidence, supplier names risk being inaccurate, which is unacceptable for licensing or litigation use.

Which companies supply the SPRAVATO nasal spray device components?

Direct answer: Device-component suppliers are not named in standard public prescribing information.

Typical nasal spray device supply chain

A nasal spray product can involve:

Plunger and metering components
Spray nozzle assemblies
Spring/plastic compression parts
Sterility assurance packaging components
Labeling and compliance inserts (REMS-related instructions)

Device suppliers are often specialized and disclosed only when:

device subcomponents are disclosed in development publications
they appear as manufacturing establishments in FDA records
they are named in litigation or inspection documents

How does REMS for SPRAVATO affect supplier and distribution workflows?

Direct answer: SPRAVATO’s REMS constrains dispensing and administration logistics but does not, by itself, identify upstream suppliers.

Supply-chain operational impacts of REMS

A REMS typically affects:

Distribution channels authorized to dispense the product
Patient enrollment and prescriber/pharmacy verification workflows
Inventory management tied to approved channels
Handling documentation for administration and follow-up

For supplier mapping, the REMS is mainly relevant to:

which wholesalers and distribution partners are used
which pharmacies receive shipments
how product movement is documented It does not provide upstream API or CMO identities.

What patent estate covers SPRAVATO formulations and manufacturing, and how does that map to supplier risk?

Direct answer: Patent coverage impacts manufacturing method and formulation pathways, but supplier names are independent of the Orange Book patent listings.

How patent strategy affects supplier selection

Even if a CMO is capable, suppliers may be blocked by:

formulation patents (composition and/or concentration)
device-related patents (metering, nozzle, delivery system)
method-of-manufacture patents
REMS-specific labeling or use instructions claims, where applicable

This becomes important in:

contract negotiations
generic supplier qualification
potential Paragraph IV pathways

What generic or biosimilar entry risks exist for SPRAVATO suppliers?

Direct answer: SPRAVATO is a small-molecule product. “Biosimilar” is not the right comparator. Competitive entry risk exists through:

NDA generics
ANDA Para IV challenges
reformulation or device changes, where allowed

Supplier implications of Para IV challenges

When generic/ANDA filers pursue entry, suppliers face:

patent defense exposure
process constraints tied to method-of-use or manufacturing patents
supply interruption risk during litigation
regulatory hold risks if manufacturing sites are implicated in compliance actions

Which wholesalers distribute SPRAVATO in the US, and are they “suppliers”?

Direct answer: Wholesalers and distributors are “supply chain suppliers” but are not upstream manufacturing suppliers. Standard product labeling often lists distributors or marketing entities, but it typically does not provide a full distributor network map.

Timeline: When did SPRAVATO’s supply chain scale in the US, and what does that imply for suppliers?

Direct answer: Without specific FDA product establishment timelines, NDA supplement history, and manufacturing site changes, a defensible scaling timeline cannot be produced from the public sources typically available in a supplier query.

Which jurisdictions matter for SPRAVATO supplier contracts: US, EU, UK?

Direct answer: For SPRAVATO procurement, the controlling suppliers for US supply are those manufacturing and releasing product under US regulatory obligations. EU/UK suppliers matter if:

the product is manufactured there and imported
EU sites support US submissions
corporate consolidation shifts release responsibilities

A jurisdiction map is only actionable when manufacturing sites and their countries are identified from FDA establishment registrations or inspection records.

What manufacturing/IP barriers could block a new CMO from supplying SPRAVATO?

Direct answer: The main barriers are regulatory and IP-related:

FDA CGMP compliance for the site and process
device compatibility and qualification
formulation/process IP constraints
validation and batch release requirements
REMS-associated packaging and labeling requirements

Because supplier names are the target of this query, barrier analysis without supplier-specific process descriptions is not useful for supplier due diligence.

Key Takeaways

Public FDA Orange Book and label materials do not provide a complete, citation-grade list of upstream suppliers for SPRAVATO’s esketamine API, nasal spray fill, or nasal device components.
Supplier mapping for SPRAVATO requires site-level evidence from FDA establishment registrations/inspection records and NDC-to-labeler/manufacturer mapping, not Orange Book patent listings.
For licensing, litigation, or procurement decisions, supplier identification without site-linked evidence risks being inaccurate and unusable.

FAQs

Does the SPRAVATO label list the API manufacturer or contract manufacturer?
How can you identify SPRAVATO manufacturing sites from FDA data for supplier due diligence?
Do SPRAVATO patents in the Orange Book restrict contract manufacturing or only formulations?
Do REMS requirements change who can receive and distribute SPRAVATO in the US?
What evidence sources best validate SPRAVATO device subcomponent suppliers (nozzle, metering, pump)?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
U.S. Food and Drug Administration. Drugs@FDA: Drug Information Portal for SPRAVATO (esketamine).

Suppliers and packagers for SPRAVATO

SPRAVATO